News

Tulane University awarded $12 million to create Lassa vaccine and treatment

The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.

Publication – VHFC researchers solve the structure of Lassa virus glycoprotein

A team of scientists at The Scripps Research Institute (TSRI) in La Jolla, California has published a study that shows the structure of the viral machinery that Lassa virus uses to enter human cells.

Publication - VHFC Researchers Publish Series of Papers on Zika Virus Epidemiology

Members of the Viral Hemorrhagic Fever Consortium recently published a series of papers that show how Zika virus spread across South America, the Caribbean, and into the United States. The researchers used sequencing technology to collect genomic data that allowed them to understand how the virus evolved and spread during the recent outbreak that began Brazil.

How to turn competitors into collaborators

In a Comment article published in the scientific journal Nature, Dr. Erica Ollmann Saphire and colleagues outline how a collaborative strategy among researchers can speed up the discovery of treatments for diseases such as Ebola and Zika.

Zalgen Labs Launches E-Commerce Platform for Hemorrhagic Fever Products

Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, today announced the launch of a new web-based marketplace to further affirm the Company as the global leader in e-commerce for hemorrhagic fever research and clinical testing.

Publication - Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013-2016 Epidemic

Abstract - The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented number of viral mutations to occur over successive human-to-human transmission events, increasing the probability that adaptation to the human host occurred during the outbreak.

Press - "I Don't Know if I'm Already Infected"

He was a globally renowned expert in tropical diseases, and the hero who ran Sierra Leone’s worst Ebola ward. So why, when he finally fell ill, was he denied the extraordinary treatments that could have saved him?

Publication - Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

Abstract - Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively.

Zalgen Labs Introduces Viral Diagnostics Business

Opens Advanced Product Development Center in Colorado

Publication - Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection

Background - The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded. Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) could exceed 5 days.

Syndicate content
PSD to Drupal theme